Liu Ban, Che Wenliang, Yan Hongwei, Zhu Weidong, Wang Hongbao
Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, China.
Intern Med. 2013;52(24):2715-9. doi: 10.2169/internalmedicine.52.0731.
Statins prevent cardiovascular events in patients with coronary artery disease (CAD). However, there is little information regarding the vascular effects of statins on arterial wall stiffness in CAD patients.
A total of 36 patients were randomly assigned to receive rosuvastatin (10 mg per day) or simvastatin/ezetimibe (10/10 mg per day) for eight weeks. The aim of the present study was to determine the effects of rosuvastatin or simvastatin/ezetimibe on arterial wall stiffness measured according to the brachial and ankle pulse wave velocity (baPWV) in CAD patients.
Both treatments significantly improved the levels of total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP) (p<0.05). The ROCK activity and baPWV were significantly improved in the rosuvastatin group compared with that observed in the simvastatin/ezetimibe group (p<0.05). The changes in baPWV were significantly correlated with the changes in the ROCK activity (r=0.488, p<0.01), but not with the changes in the lipid profile or the hs-CRP level.
Compared with simvastatin/ezetimibe (10/10 mg), rosuvastatin (10 mg) appears to more effectively improve arterial wall stiffness that may be mediated by modulation of the ROCK activity.
他汀类药物可预防冠心病（CAD）患者发生心血管事件。然而，关于他汀类药物对CAD患者动脉壁僵硬度的血管效应的信息却很少。
总共36例患者被随机分配接受瑞舒伐他汀（每日10毫克）或辛伐他汀/依折麦布（每日10/10毫克）治疗8周。本研究的目的是确定瑞舒伐他汀或辛伐他汀/依折麦布对根据肱踝脉搏波速度（baPWV）测量的CAD患者动脉壁僵硬度的影响。
两种治疗均显著改善了总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）和高敏C反应蛋白（hs-CRP）的水平（p<0.05）。与辛伐他汀/依折麦布组相比，瑞舒伐他汀组的ROCK活性和baPWV显著改善（p<0.05）。baPWV的变化与ROCK活性的变化显著相关（r=0.488，p<0.01），但与血脂谱或hs-CRP水平的变化无关。
与辛伐他汀/依折麦布（10/10毫克）相比，瑞舒伐他汀（10毫克）似乎能更有效地改善动脉壁僵硬度，这可能是通过调节ROCK活性介导的。
